93 related articles for article (PubMed ID: 17407132)
1. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative Effects of Epigenetic Modifier Drugs Through E-cadherin Up-regulation in Liver Cancer Cell Lines.
Uribe D; Cardona A; Esposti DD; Cros MP; Cuenin C; Herceg Z; Camargo M; Cortés-Mancera FM
Ann Hepatol; 2018; 17(3):444-460. PubMed ID: 29735783
[TBL] [Abstract][Full Text] [Related]
3. Combination effect of epigenetic regulation and ionizing radiation in colorectal cancer cells.
Kim JG; Bae JH; Kim JA; Heo K; Yang K; Yi JM
PLoS One; 2014; 9(8):e105405. PubMed ID: 25136811
[TBL] [Abstract][Full Text] [Related]
4. Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.
Facciotto C; Casado J; Turunen L; Leivonen SK; Tumiati M; Rantanen V; Kauppi L; Lehtonen R; Leppä S; Wennerberg K; Hautaniemi S
Clin Epigenetics; 2019 Dec; 11(1):192. PubMed ID: 31829282
[TBL] [Abstract][Full Text] [Related]
5. Normalization of the ATP1A1 Signalosome Rescinds Epigenetic Modifications and Induces Cell Autophagy in Hepatocellular Carcinoma.
Rajan PK; Udoh US; Nakafuku Y; Pierre SV; Sanabria J
Cells; 2023 Sep; 12(19):. PubMed ID: 37830582
[TBL] [Abstract][Full Text] [Related]
6. A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
Wu B; Tapadar S; Ruan Z; Sun CQ; Arnold RS; Olugbami JO; Johnston A; Arunsi U; Gaul DA; Petros JA; Kobayashi T; Duda DG; Oyelere AK
bioRxiv; 2024 Mar; ():. PubMed ID: 38585757
[TBL] [Abstract][Full Text] [Related]
7. Targeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma.
Demir S; Razizadeh N; Indersie E; Branchereau S; Cairo S; Kappler R
Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285887
[TBL] [Abstract][Full Text] [Related]
8. Thymoquinone, piperine, and sorafenib combinations attenuate liver and breast cancers progression: epigenetic and molecular docking approaches.
El-Shehawy AA; Elmetwalli A; El-Far AH; Mosallam SAE; Salama AF; Babalghith AO; Mahmoud MA; Mohany H; Gaber M; El-Sewedy T
BMC Complement Med Ther; 2023 Mar; 23(1):69. PubMed ID: 36870998
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
10. Roles and regulation of histone acetylation in hepatocellular carcinoma.
Xia JK; Qin XQ; Zhang L; Liu SJ; Shi XL; Ren HZ
Front Genet; 2022; 13():982222. PubMed ID: 36092874
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway.
Tonon F; Cemazar M; Kamensek U; Zennaro C; Pozzato G; Caserta S; Ascione F; Grassi M; Guido S; Ferrari C; Cansolino L; Trotta F; Kuzmanov BG; Forte G; Martino F; Perrone F; Bomben R; Gattei V; Elvassore N; Murano E; Truong NH; Olson M; Farra R; Grassi G; Dapas B
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406401
[TBL] [Abstract][Full Text] [Related]
12. Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma.
Sanaei M; Kavoosi F
Res Pharm Sci; 2021 Jun; 16(3):260-268. PubMed ID: 34221059
[TBL] [Abstract][Full Text] [Related]
13. Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells.
Zhang H; Li G; Zhang Y; Shi J; Yan B; Tang H; Chen S; Zhang J; Wen P; Wang Z; Pang C; Li J; Guo W; Zhang S
Front Oncol; 2019; 9():1471. PubMed ID: 31993368
[No Abstract] [Full Text] [Related]
14. Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis.
Li D; Zeng Z
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31320544
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
Suraweera A; O'Byrne KJ; Richard DJ
Front Oncol; 2018; 8():92. PubMed ID: 29651407
[TBL] [Abstract][Full Text] [Related]
16. Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.
Liu KY; Wang LT; Hsu SH
Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29301348
[TBL] [Abstract][Full Text] [Related]
17. GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition.
Enane FO; Shuen WH; Gu X; Quteba E; Przychodzen B; Makishima H; Bodo J; Ng J; Chee CL; Ba R; Seng Koh L; Lim J; Cheong R; Teo M; Hu Z; Ng KP; Maciejewski J; Radivoyevitch T; Chung A; Ooi LL; Tan YM; Cheow PC; Chow P; Chan CY; Lim KH; Yerian L; Hsi E; Toh HC; Saunthararajah Y
J Clin Invest; 2017 Sep; 127(9):3527-3542. PubMed ID: 28758902
[TBL] [Abstract][Full Text] [Related]
18. Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma.
Kgatle MM; Setshedi M; Hairwadzi HN
Biomed Res Int; 2016; 2016():3956485. PubMed ID: 28105421
[TBL] [Abstract][Full Text] [Related]
19. UHRF2 decreases H3K9ac expression by interacting with it through the PHD and SRA/YDG domain in HepG2 hepatocellular carcinoma cells.
Zhang T; Zhao L; Zeng S; Bai L; Chen J; Zhang Z; Wang Y; Duan C
Int J Mol Med; 2017 Jan; 39(1):126-134. PubMed ID: 28004105
[TBL] [Abstract][Full Text] [Related]
20. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.
Goto K; Annan DA; Morita T; Li W; Muroyama R; Matsubara Y; Ito S; Nakagawa R; Tanoue Y; Jinushi M; Kato N
Sci Rep; 2016 Dec; 6():38407. PubMed ID: 27910927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
